Sheet	1	of	2	
JIICCI.		UI		

	(. Sign
FORM PTO-1449	MAY 2 4 2004
LIST OF DISCLOSE	JRES CHEELEEMAPPLICAN

(Use several sheets if necessary)

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No. Serial No. 10/624,153

Applicant

Yvonne Chen et al.

Filing Date 21 Jul 2003 Group 1641

U.S. PATENT DOCUMENTS

Exam Initial				Document Number	Date	Name	Class	Subclass	Filing Date
LA	B	ŀ	1	5,821,337	13.10.98	Carter et al.			
		ŀ	2	6,010,861	04.01.00	Blume, A.			
	,	ŀ	3	6,037,454	14.03.00	Jardieu et al.			

FOREIGN PATENT DOCUMENTS

Examine Initials	er		Document Number	Date	Country	Class	Subclass	Transla Yes	ition No
LAB	ŀ	4	2,125,240	07.12.95	CANADA				
l.	-	• 5	91-40386	03.06.97	JAPAN (ABSTRACT ONLY)				
.	ŀ	6	WO 97/31024	28.08.97	PCT				
	+	* 7	WO 98/23746	04.06.98	PCT				•
	-	8	WO 98/23761	04.06.98	PCT				
ļ.	+	• 9	WO 98/45331	15.10.98	PCT				
	ŀ	*10	WO 98/45332	15.10.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

-			official designation and the second s				
4	48		Amit et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 A Resolution" <u>Science</u> 233:747-753 (Aug 1986)				
		*12	Balint and Larrick, "Antibody engineering by parsimonious mutagenesis" <u>Gene</u> 137(1):109-118 (Dec 27, 1993				
		*13 .	Barbas III et al., "In Vitro Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity." Proc. Natl. Acad. Sci. USA 91(9):3809-3813 (Apr 26, 1994)				
		*14	Brunger et al., "Crystallographic R factor refinement by molecular dynamics" <u>Science</u> 235:458-460 (Jan 23, 1987)				
		*15	Chiswell and McCafferty, "Phage antibodies: will new 'colicional' antibodies replace monoclonal antibodies?" Trends In Biotechnology 10(3):80-84 (Mar 1992)				
		*16	Fenney and Thuerauf, "Sequence and fine specificity analysis of primary 511 anti-phosphorylcholine antibodies" <u>Journal of Immunology</u> 143(12):4061-4068 (Dec 15, 1989)				
		*17	Gazzano-Santoro et al., "A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody." <u>Journal of Immunological Methods</u> , 202:163-171 (1997)				
		*18	Groves et al., "Production of an ovine monoclonal antibody to testosterone by an interspecies fusion" Hybridoma 6(1):71-76 (Feb 1987)				
		*19	Hawkins et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation" <u>J.</u> <u>Mol. Biol.</u> 226:889-896 (1992)				
			Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a				

Mouse." Nature. 321:522-525 (May 29, 1986)

Kabat. <u>Sequences of Proteins of Immunological Interest</u>, US Dept of Health and Human Services, NIH, 5th edition, Bethesda, MD (1991)

LeBlanc et al., "Recognition properties of a sequence-specific DNA binding antibody" <u>Biochemistry</u> 37(17):6015-6022 (Apr 28, 1998)

Examiner 2 - 1

*22

Date Considered .

r draw line through citation

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM	PTO-	449 U.S. Dept. of Commerce	Atty Docket No.	Serial No.			
		Patent and Trademark Office	P1469R1C1 10/624,153				
LICT	OF 01	, 	Applicant				
LIST	OF DI	SCLOSURES CITED BY APPLICANT	Yvonne Chen et al'.				
(L	Jse sev	eral sheets if necessary)	Filing Date	Group			
			21 Jul 2003	1641			
	OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)						
LAB	+23	Lee et al., "Strong inhibition of fibrinogen binding to plateled installed into a presentation scaffold" Protein Engineering 6(7)	:745-754 (Sep 1993)				
	*.24	McLane et al., "Transplantation of a 17-amino acid α-helical DNA-binding domain into an antibody molecule confers sequence-dependent DNA recognition" Proc. USA 92(11):5214-5218 (23, 1995)					
	*25	Muller et al., "VEGF and the Fab fragment of a humanized neutral complex at 2.4 A resolution and mutational analysis of the inter 1998)	face Structure 6(9)	:1153-1167 (Sep 15,			
	*26	Ohlin and Borrebaeck, "Insertions and deletions in hypervariable contribute to molecular diversity" Molecular Immunology 35(4):2:	33-238 (Mar 1998)				
	*27	Panka et al., "Variable region framework differences result in c variant anti-digoxin antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 85:	3080-3084 (May 1988)				
	*28	Presta et al., "Humanization of an Anti-Vascular Endothelial Gro Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57	(20):4593-4599 (Oct 1	5, 1997)			
	+29	Rader and Barbas III, "Phage display of combinatorial antibody Biotechnology 8(4):503-508 (Aug 1997)					
	*30	Rudikoff et al., "Single amino acid substitution altering antigo Sci. USA 79:1979-1983 (1982)					
	*31	Schier et al., "Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site" <u>Journal of Molecula</u> Biology 263(4):551-567 (Nov 8, 1996)					
	*32	Sheets et al., *Efficient construction of a large nonimmune phage antibody library: the production of high-affinity human single-chain antibodies to protein antigens* Proc. Natl. Acad. Sci. USA (May 26, 1998)					
	+33	Simon and Rajewsky, "A functional antibody mutant with an insert the $V_{\rm H}$ domain: implications for antibody engineering" Protein Er	<u>ngineering</u> 5(3):229-2	34 (Apr 1992)			
	*34.	Thompson et al., "Affinity maturation of a high-affinity human r hypervariable loop of human immunodeficiency virus: use of phage strain reactivity" <u>Journal of Molecular Biology</u> 256(1):77-88 (Fe	e display to improve ab 16, 1996)	affinity and broaden			
	*35	Wilson et al., *Somatic hypermutation introduces insertions and Journal of Experimental Medicine 187(1):59-70 (Jan 5, 1998)					
	*36	Wu et al., 'Stepwise in vitro affinity maturation of Vitaxin, an Natl. Acad. Sci. USA 95(11):6037-6042 (May 26, 1998)					
	*37	Yang et al., "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibodinto the picomolar range" <u>Journal of Molecular Biology</u> 254(3):392-403 (Dec 1, 1995)					
	*38	Zhao et al., "A paradigm for drug discovery using a conformation presentation scaffold" Nature Structural Biology 2(12):1131-113		ructure of a			
	 			·			
	<u> </u>	-					
	}						
4 1-							
		·		l,			
Examin	er 🔥	Da	te Considered				
L.	Ku_	m Ruste	4/11/06	44.			
*Exami	nėr: In in con	If reference considered, whether or not citation is in conformance with MPEP formance and not considered. Include copy of this form with next communication to	609; draw line through cita o applicant.	tion			